EMA, Bayer and Pfizer Involved in Release of Draft Opinion on Nonclinical Animal Replacement 'Virtual Control Group'
Regulatory Shift Toward Replacing Nonclinical Animal Studies with Virtual Data
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has released a draft qualification opinion on the use of a 'Virtual Control Group (VCG)' that replaces animal control groups with computer modeling at the nonclinical stage. This measure aims to reduce the number of mice or rats traditionally required as concurrent control groups in new drug safety assessments, thereby addressing ethical concerns and lowering preclinical costs. The initiation of a formal regulatory validation process for AI- and digital-data‑based replacement methodologies represents a significant shift with substantial industry impact.
€30 Million VICT3R Consortium United by 23 Global Big‑Pharma Companies
The guidance is led by the VICT3R Consortium, which receives funding from the European Innovation in Health Initiative (IHI). The project involves 37 partners and is financed at €30 million (approximately KRW 45 billion) for a 42‑month period from September 2024 to February 2028. Bayer AG and the University of Pompeu Fabra serve as co‑chairs, while Pfizer, AstraZeneca, Novartis and other global pharmaceutical companies collaborate to standardize historical nonclinical control data.
Cost Reduction and Accelerated Timelines in New‑Drug Development
The VCG methodology can reduce animal usage in early toxicity studies (e.g., non‑GLP rat DRF studies) by up to 25 %. Given that toxicity assessment accounts for roughly 40 % of the nonclinical CRO market, which is projected to reach USD 90 billion by 2026, the cost burden on developers could be substantially lowered. Moreover, high‑fidelity computer models that simulate safety data can shorten the trial‑and‑error phase preceding Phase 1, thereby enhancing the capital efficiency and valuation of drug candidates.
Establishing Global Regulatory Standards and the Dawn of Digital Biology
The EMA conducted a public consultation from 31 March to 12 May 2026 and intends to incorporate the feedback into a final Qualification Opinion. This regulatory framework will serve as the institutional basis for recognizing VCG data as officially valid in future marketing authorization applications (MAA). Starting with rat toxicity studies, the virtual control concept could be expanded across the regulatory safety landscape, positioning big‑pharma companies and technology firms with digital‑twin capabilities to shape the future of nonclinical strategy.
The EMA’s release of the draft Virtual Control Group (VCG) guideline, anchored by the €30 million VICT3R consortium, is poised to exert a substantial impact on the global nonclinical CRO market, which is estimated at roughly USD 90 billion in 2026. With 23 pharmaceutical companies—including Bayer and Pfizer—participating, the methodology satisfies the ethical 3Rs principle while delivering an approximate 25 % reduction in the cost of essential safety and toxicity testing at the nonclinical stage. Upon regulatory approval, the approach will increase throughput of nonclinical toxicology studies and shorten development timelines, markedly accelerating the progression of pipelines into Phase 1. This also creates a new regulatory avenue for technology firms equipped with AI and Digital Twin capabilities to rapidly enter the traditional pharma‑biotech ecosystem’s toxicology service market.